Smurf1-IN-A01 is an inhibitor of negatively regulatory factor Smurf1 for promoting bone formation.

FKBP12 PROTAC dTAG-13 (dTAG-13) is an in vivo-active heterobifunctional adation tag (dTAG) small molecule that engage FKBP12F36V and CRBN, selectively degrade FKBP12F36V in a CRBN-dependent manner in cells.

FKBP12 PROTAC dTAG-7 (dTAG-7) is a cell-permeable heterobifunctional adation tag (dTAG) small molecule that engage FKBP12F36V and CRBN, selectively degrade FKBP12F36V in a CRBN-dependent manner in cells.

SRA737 is a highly potent, selective, ATP-competitive inhibitor of Chk1 with IC50 of 1.3 nM.

DJ101is a potent and metabolically stable tubulin inhibitor that can circumvent the drug efflux pumps responsible for multidrug resistance of existing tubulin inhibitors.

ACT-389949 is a novel potent and selective formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) agonist with EC50 of 3 nM, shows potential for the treatment of inflammatory disorders..

ADH-503, reduced myeloid cell recruitment and altered the phenotypes of myeloid cells within the tumor. ADH-503 treatment increased responses to chemotherapy or radiation and also rendered normally resistant tumors sensitive to checkpoint blockade, as T c

BRITE338733 is a novel ATPase inhibitor.

cFMS Receptor Inhibitor II is a cell-permeable anilinoquinoline compound that acts as a strong, active site-targeting inhibitor of MCSF receptor/cFMS.

D3263 is a novel, orally bioavailable small molecule Trp-p8 agonist.

GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM.

SB297006 is a CCR3 antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells.

Ingliforib is a glycogen phosphorylase inhibitor, with IC50s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity.

JBSNF-000088 (6-Methoxynicotinamide) is a small molecule nicotinamide analog that inhibits Nicotinamide N-methyltransferase (NNMT) with IC50 of 1.8, 2.8 and 5.0?μM for human, monkey and mouse NNMT, respectively.

KY-226 (KY226) is a potent, allosteric, orally active inhibitor of protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.28 uM (human PTP1B), does not exhibit PPARγ agonist activity.

Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling.

ML367 is a potent inhibitor of ATPase family AAA domain-containing protein 5 (ATAD5) stabilization, acts as a probe molecule that has low micromolar inhibitory activity.

MRT-68921 hydrochloride (MRT68921) is a potent, relatively specific inhibitor of both ULK1 and ULK2 with IC50 of 2.9 and 1.1 nM, respectively.

CP-945598 HCl is a potent and selective cannabinoid type 1 receptor antagonist with Ki of 0.7 nM.

PDM 11 is a potent and selective aryl hydrocarbon receptor (AhR) antagonist.

PF 3845 is a selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 uM).

Pirozadil is a hypolipidemic agent.

PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 by covalent cysteine modification, without compromising DNA binding.

PK11007 is a thiol-reactive anticancer agent that stabilizes wild type and mutant p53 through selective alkylation of two surface cysteines without interfering with its DNA binding.

PXS-5153A (PXS5153A) is a potent, selective, fast-acting, dual LOXL2/LOXL3 inhibitor with IC50 of <40 nM against all mammalian species LOXL2, inhibits human LOXL3 with IC50 of 63 nM.

SPHINX31 is a potent inhibitor of serine/arginine-rich protein kinase 1 (SRPK1; IC50 = 5.9 nM).

SRI-011381 is an agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease.

XMU-MP-1 is a reversible and selective MST1/2 inhibitor with IC50 values of 71.1 ± 12.9 nM and 38.1 ± 6.9 nM against MST1 and MST2, respectively.

Sulfaphenazole is an inhibitor of CYP2C9 (Ki = 0.3 μM) that demonstrates at least 100-fold selectivity over other CYP450 isoforms (Kis = 63 and 29 μM for CYP2C8 and CYP2C18, respectively, and no activity at CYP1A1, CYP1A2, CYP3A4, CYP2C19).

SRT3109 is an antagonist of CXCR2, with a pIC50 of 8.2, and used in the research of chemokine mediated diseases.